Jennifer L Rosenbaum1, Susan J Melhorn2,3, Stefan Schoen4, Mary F Webb2,3, Mary Rosalynn B De Leon2,3, Madelaine Humphreys2,3, Kristina M Utzschneider1,5, Ellen A Schur2,3. 1. Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, WA. 2. Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, WA. 3. UW Medicine Diabetes Institute, University of Washington, Seattle, WA. 4. University of Washington School of Medicine, Seattle, WA. 5. Research and Development, Department of Veterans Affairs, Seattle, WA.
Abstract
OBJECTIVE: Preclinical research implicates hypothalamic glial cell responses in the pathogenesis of obesity and type 2 diabetes (T2D). In the current study we sought to translate such findings to humans by testing whether radiologic markers of gliosis in the mediobasal hypothalamus (MBH) were greater in individuals with obesity and impaired glucose homeostasis or T2D. RESEARCH DESIGN AND METHODS: Using cross-sectional and prospective cohort study designs, we applied a validated quantitative MRI approach to assess gliosis in 67 adults with obesity and normal glucose tolerance, impaired glucose tolerance (IGT), or T2D. Assessments of glucose homeostasis were conducted via oral glucose tolerance tests (OGTT) and β-cell modeling. RESULTS: We found significantly greater T2 relaxation times (a marker of gliosis by MRI), that were independent of adiposity, in the groups with IGT and T2D as compared with the group with normal glucose tolerance. Findings were present in the MBH, but not control regions. Moreover, positive linear associations were present in the MBH but not control regions between T2 relaxation time and glucose area under the curve during an OGTT, fasting glucose concentrations, hemoglobin A1c, and visceral adipose tissue mass, whereas negative linear relationships were present in the MBH for markers of insulin sensitivity and β-cell function. In a prospective cohort study, greater MBH T2 relaxation times predicted declining insulin sensitivity over 1 year. CONCLUSIONS: Findings support a role for hypothalamic gliosis in the progression of insulin resistance in obesity and thus T2D pathogenesis in humans.
OBJECTIVE: Preclinical research implicates hypothalamic glial cell responses in the pathogenesis of obesity and type 2 diabetes (T2D). In the current study we sought to translate such findings to humans by testing whether radiologic markers of gliosis in the mediobasal hypothalamus (MBH) were greater in individuals with obesity and impaired glucose homeostasis or T2D. RESEARCH DESIGN AND METHODS: Using cross-sectional and prospective cohort study designs, we applied a validated quantitative MRI approach to assess gliosis in 67 adults with obesity and normal glucose tolerance, impaired glucose tolerance (IGT), or T2D. Assessments of glucose homeostasis were conducted via oral glucose tolerance tests (OGTT) and β-cell modeling. RESULTS: We found significantly greater T2 relaxation times (a marker of gliosis by MRI), that were independent of adiposity, in the groups with IGT and T2D as compared with the group with normal glucose tolerance. Findings were present in the MBH, but not control regions. Moreover, positive linear associations were present in the MBH but not control regions between T2 relaxation time and glucose area under the curve during an OGTT, fasting glucose concentrations, hemoglobin A1c, and visceral adipose tissue mass, whereas negative linear relationships were present in the MBH for markers of insulin sensitivity and β-cell function. In a prospective cohort study, greater MBH T2 relaxation times predicted declining insulin sensitivity over 1 year. CONCLUSIONS: Findings support a role for hypothalamic gliosis in the progression of insulin resistance in obesity and thus T2D pathogenesis in humans.
Authors: Martin Jastroch; Silke Morin; Matthias H Tschöp; Chun-Xia Yi Journal: Best Pract Res Clin Endocrinol Metab Date: 2014-03-06 Impact factor: 4.690
Authors: Carina Kreutzer; Sönke Peters; Dominik M Schulte; Daniela Fangmann; Kathrin Türk; Stephan Wolff; Thilo van Eimeren; Markus Ahrens; Jan Beckmann; Clemens Schafmayer; Thomas Becker; Tina Kerby; Axel Rohr; Christian Riedel; Femke-Anouska Heinsen; Frauke Degenhardt; Andre Franke; Philip Rosenstiel; Nana Zubek; Christian Henning; Sandra Freitag-Wolf; Astrid Dempfle; Aristea Psilopanagioti; Helen Petrou-Papadaki; Lennart Lenk; Olav Jansen; Stefan Schreiber; Matthias Laudes Journal: Diabetes Date: 2017-06-02 Impact factor: 9.461
Authors: Kathryn E Berkseth; Stephan J Guyenet; Susan J Melhorn; Donghoon Lee; Joshua P Thaler; Ellen A Schur; Michael W Schwartz Journal: Endocrinology Date: 2014-06-10 Impact factor: 4.736
Authors: Caroline Baufeld; Anja Osterloh; Stefan Prokop; Kelly R Miller; Frank L Heppner Journal: Acta Neuropathol Date: 2016-07-08 Impact factor: 17.088
Authors: Juliana C Moraes; Andressa Coope; Joseane Morari; Dennys E Cintra; Erika A Roman; José R Pauli; Talita Romanatto; José B Carvalheira; Alexandre L R Oliveira; Mario J Saad; Licio A Velloso Journal: PLoS One Date: 2009-04-02 Impact factor: 3.240
Authors: Ellen A Schur; Susan J Melhorn; Seok-Kyun Oh; J Matthew Lacy; Kathryn E Berkseth; Stephan J Guyenet; Joshua A Sonnen; Vidhi Tyagi; Mary Rosalynn; B De Leon; Mary F Webb; Zenobia T Gonsalves; Corinne L Fligner; Michael W Schwartz; Kenneth R Maravilla Journal: Obesity (Silver Spring) Date: 2015-11 Impact factor: 5.002
Authors: Cristina García-Cáceres; Carmelo Quarta; Luis Varela; Yuanqing Gao; Tim Gruber; Beata Legutko; Martin Jastroch; Pia Johansson; Jovica Ninkovic; Chun-Xia Yi; Ophelia Le Thuc; Klara Szigeti-Buck; Weikang Cai; Carola W Meyer; Paul T Pfluger; Ana M Fernandez; Serge Luquet; Stephen C Woods; Ignacio Torres-Alemán; C Ronald Kahn; Magdalena Götz; Tamas L Horvath; Matthias H Tschöp Journal: Cell Date: 2016-08-11 Impact factor: 41.582
Authors: Kristina M Utzschneider; Ronald L Prigeon; Mirjam V Faulenbach; Jenny Tong; Darcy B Carr; Edward J Boyko; Donna L Leonetti; Marguerite J McNeely; Wilfred Y Fujimoto; Steven E Kahn Journal: Diabetes Care Date: 2008-10-28 Impact factor: 19.112